Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
25
SONA.CX Quote, Financials, Valuation and Earnings
Last price:
$0.46
Seasonality move
:
-2.72%
Day range:
$0.44 - $0.49
52-week range:
$0.24 - $0.91
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
155.22x
Volume:
17.6K
Avg. volume:
38.2K
1-year change:
84%
Market cap:
$52M
Revenue:
--
EPS (TTM):
-$0.03
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SONA.CX
Sona Nanotech, Inc.
|
-- | -- | -- | -- | -- |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
-- | -- | -- | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SONA.CX
Sona Nanotech, Inc.
|
$0.46 | -- | $52M | -- | $0.00 | 0% | -- |
|
COOL.CX
Core One Labs, Inc.
|
$0.15 | -- | $6.8M | -- | $0.00 | 0% | 32.71x |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
HEAL.CX
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
$0.05 | -- | $9.7M | -- | $0.00 | 0% | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
$0.0200 | -- | $205.5K | 0.52x | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SONA.CX
Sona Nanotech, Inc.
|
56.54% | 0.418 | 0.66% | 0.40x |
|
COOL.CX
Core One Labs, Inc.
|
-- | 0.000 | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | 0.000 | -- | -- |
|
HEAL.CX
|
-- | 0.000 | -- | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
40.99% | -3.518 | 19.05% | 2.85x |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-3.43% | 1.456 | 20.53% | 0.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SONA.CX
Sona Nanotech, Inc.
|
-$180K | -$897K | -202.57% | -286.52% | -- | -$404.5K |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
-- | -$1.1M | -1117.27% | -- | -- | -$408.2K |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -$72.1K | -- | -- | -- | -$92.1K |
Sona Nanotech, Inc. vs. Competitors
-
Which has Higher Returns SONA.CX or COOL.CX?
Core One Labs, Inc. has a net margin of -- compared to Sona Nanotech, Inc.'s net margin of --. Sona Nanotech, Inc.'s return on equity of -286.52% beat Core One Labs, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SONA.CXSona Nanotech, Inc.-- -$0.01 $771.7K COOL.CXCore One Labs, Inc.-- -- -- -
What do Analysts Say About SONA.CX or COOL.CX?
Sona Nanotech, Inc. has a consensus price target of --, signalling upside risk potential of 204.35%. On the other hand Core One Labs, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Sona Nanotech, Inc. has higher upside potential than Core One Labs, Inc., analysts believe Sona Nanotech, Inc. is more attractive than Core One Labs, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SONA.CXSona Nanotech, Inc.0 0 0 COOL.CXCore One Labs, Inc.0 0 0 -
Is SONA.CX or COOL.CX More Risky?
Sona Nanotech, Inc. has a beta of 0.749, which suggesting that the stock is 25.106% less volatile than S&P 500. In comparison Core One Labs, Inc. has a beta of 0.495, suggesting its less volatile than the S&P 500 by 50.458%.
-
Which is a Better Dividend Stock SONA.CX or COOL.CX?
Sona Nanotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Core One Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sona Nanotech, Inc. pays -- of its earnings as a dividend. Core One Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SONA.CX or COOL.CX?
Sona Nanotech, Inc. quarterly revenues are --, which are larger than Core One Labs, Inc. quarterly revenues of --. Sona Nanotech, Inc.'s net income of -$900K is higher than Core One Labs, Inc.'s net income of --. Notably, Sona Nanotech, Inc.'s price-to-earnings ratio is -- while Core One Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sona Nanotech, Inc. is -- versus 32.71x for Core One Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SONA.CXSona Nanotech, Inc.-- -- -- -$900K COOL.CXCore One Labs, Inc.32.71x -- -- --
-
Which has Higher Returns SONA.CX or CURE.X.CX?
Biocure Technology has a net margin of -- compared to Sona Nanotech, Inc.'s net margin of --. Sona Nanotech, Inc.'s return on equity of -286.52% beat Biocure Technology's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SONA.CXSona Nanotech, Inc.-- -$0.01 $771.7K CURE.X.CXBiocure Technology-- -- -- -
What do Analysts Say About SONA.CX or CURE.X.CX?
Sona Nanotech, Inc. has a consensus price target of --, signalling upside risk potential of 204.35%. On the other hand Biocure Technology has an analysts' consensus of -- which suggests that it could fall by --. Given that Sona Nanotech, Inc. has higher upside potential than Biocure Technology, analysts believe Sona Nanotech, Inc. is more attractive than Biocure Technology.
Company Buy Ratings Hold Ratings Sell Ratings SONA.CXSona Nanotech, Inc.0 0 0 CURE.X.CXBiocure Technology0 0 0 -
Is SONA.CX or CURE.X.CX More Risky?
Sona Nanotech, Inc. has a beta of 0.749, which suggesting that the stock is 25.106% less volatile than S&P 500. In comparison Biocure Technology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SONA.CX or CURE.X.CX?
Sona Nanotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biocure Technology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sona Nanotech, Inc. pays -- of its earnings as a dividend. Biocure Technology pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SONA.CX or CURE.X.CX?
Sona Nanotech, Inc. quarterly revenues are --, which are larger than Biocure Technology quarterly revenues of --. Sona Nanotech, Inc.'s net income of -$900K is higher than Biocure Technology's net income of --. Notably, Sona Nanotech, Inc.'s price-to-earnings ratio is -- while Biocure Technology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sona Nanotech, Inc. is -- versus -- for Biocure Technology. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SONA.CXSona Nanotech, Inc.-- -- -- -$900K CURE.X.CXBiocure Technology-- -- -- --
-
Which has Higher Returns SONA.CX or HEAL.CX?
has a net margin of -- compared to Sona Nanotech, Inc.'s net margin of --. Sona Nanotech, Inc.'s return on equity of -286.52% beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SONA.CXSona Nanotech, Inc.-- -$0.01 $771.7K HEAL.CX-- -- -- -
What do Analysts Say About SONA.CX or HEAL.CX?
Sona Nanotech, Inc. has a consensus price target of --, signalling upside risk potential of 204.35%. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that Sona Nanotech, Inc. has higher upside potential than , analysts believe Sona Nanotech, Inc. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings SONA.CXSona Nanotech, Inc.0 0 0 HEAL.CX0 0 0 -
Is SONA.CX or HEAL.CX More Risky?
Sona Nanotech, Inc. has a beta of 0.749, which suggesting that the stock is 25.106% less volatile than S&P 500. In comparison has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SONA.CX or HEAL.CX?
Sona Nanotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sona Nanotech, Inc. pays -- of its earnings as a dividend. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SONA.CX or HEAL.CX?
Sona Nanotech, Inc. quarterly revenues are --, which are larger than quarterly revenues of --. Sona Nanotech, Inc.'s net income of -$900K is higher than 's net income of --. Notably, Sona Nanotech, Inc.'s price-to-earnings ratio is -- while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sona Nanotech, Inc. is -- versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SONA.CXSona Nanotech, Inc.-- -- -- -$900K HEAL.CX-- -- -- --
-
Which has Higher Returns SONA.CX or LOBE.CX?
Lobe Sciences Ltd. has a net margin of -- compared to Sona Nanotech, Inc.'s net margin of --. Sona Nanotech, Inc.'s return on equity of -286.52% beat Lobe Sciences Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SONA.CXSona Nanotech, Inc.-- -$0.01 $771.7K LOBE.CXLobe Sciences Ltd.-- -$0.01 $5.9M -
What do Analysts Say About SONA.CX or LOBE.CX?
Sona Nanotech, Inc. has a consensus price target of --, signalling upside risk potential of 204.35%. On the other hand Lobe Sciences Ltd. has an analysts' consensus of -- which suggests that it could grow by 14192.33%. Given that Lobe Sciences Ltd. has higher upside potential than Sona Nanotech, Inc., analysts believe Lobe Sciences Ltd. is more attractive than Sona Nanotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SONA.CXSona Nanotech, Inc.0 0 0 LOBE.CXLobe Sciences Ltd.0 0 0 -
Is SONA.CX or LOBE.CX More Risky?
Sona Nanotech, Inc. has a beta of 0.749, which suggesting that the stock is 25.106% less volatile than S&P 500. In comparison Lobe Sciences Ltd. has a beta of 0.215, suggesting its less volatile than the S&P 500 by 78.507%.
-
Which is a Better Dividend Stock SONA.CX or LOBE.CX?
Sona Nanotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lobe Sciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sona Nanotech, Inc. pays -- of its earnings as a dividend. Lobe Sciences Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SONA.CX or LOBE.CX?
Sona Nanotech, Inc. quarterly revenues are --, which are smaller than Lobe Sciences Ltd. quarterly revenues of --. Sona Nanotech, Inc.'s net income of -$900K is higher than Lobe Sciences Ltd.'s net income of -$1.1M. Notably, Sona Nanotech, Inc.'s price-to-earnings ratio is -- while Lobe Sciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sona Nanotech, Inc. is -- versus -- for Lobe Sciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SONA.CXSona Nanotech, Inc.-- -- -- -$900K LOBE.CXLobe Sciences Ltd.-- -- -- -$1.1M
-
Which has Higher Returns SONA.CX or NSHS.CX?
NanoSphere Health Sciences, Inc. has a net margin of -- compared to Sona Nanotech, Inc.'s net margin of --. Sona Nanotech, Inc.'s return on equity of -286.52% beat NanoSphere Health Sciences, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SONA.CXSona Nanotech, Inc.-- -$0.01 $771.7K NSHS.CXNanoSphere Health Sciences, Inc.-- -$0.00 -$1.8M -
What do Analysts Say About SONA.CX or NSHS.CX?
Sona Nanotech, Inc. has a consensus price target of --, signalling upside risk potential of 204.35%. On the other hand NanoSphere Health Sciences, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Sona Nanotech, Inc. has higher upside potential than NanoSphere Health Sciences, Inc., analysts believe Sona Nanotech, Inc. is more attractive than NanoSphere Health Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SONA.CXSona Nanotech, Inc.0 0 0 NSHS.CXNanoSphere Health Sciences, Inc.0 0 0 -
Is SONA.CX or NSHS.CX More Risky?
Sona Nanotech, Inc. has a beta of 0.749, which suggesting that the stock is 25.106% less volatile than S&P 500. In comparison NanoSphere Health Sciences, Inc. has a beta of 0.627, suggesting its less volatile than the S&P 500 by 37.292%.
-
Which is a Better Dividend Stock SONA.CX or NSHS.CX?
Sona Nanotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoSphere Health Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sona Nanotech, Inc. pays -- of its earnings as a dividend. NanoSphere Health Sciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SONA.CX or NSHS.CX?
Sona Nanotech, Inc. quarterly revenues are --, which are smaller than NanoSphere Health Sciences, Inc. quarterly revenues of --. Sona Nanotech, Inc.'s net income of -$900K is lower than NanoSphere Health Sciences, Inc.'s net income of -$13.1K. Notably, Sona Nanotech, Inc.'s price-to-earnings ratio is -- while NanoSphere Health Sciences, Inc.'s PE ratio is 0.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sona Nanotech, Inc. is -- versus -- for NanoSphere Health Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SONA.CXSona Nanotech, Inc.-- -- -- -$900K NSHS.CXNanoSphere Health Sciences, Inc.-- 0.52x -- -$13.1K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Buy
80
TVTX alert for Dec 27
Travere Therapeutics, Inc. [TVTX] is down 1.54% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
